Men with susceptibility for prostate cancer will soon be identifiable through a simple DNA test.
Scientists have designed a blood test that reads genetic changes like a barcode - and can pick out aggressive prostate cancers by their particular pattern of gene activity.
Men who develop prostate cancer could avoid having unnecessary surgery or radiotherapy thanks to a new, more precise genetic test which is being trialed in Leeds.
Karim Kader, MD, PhD, associate clinical professor at the UC San Diego School of Medicine, together with a team of researchers from Wake Forest University School of Medicine, have developed a genetic test to predict a man's risk for prostate cancer. Use of the test could reduce the need for repeat biopsies in men who have had a negative biopsy.
Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy.
Revolutionary genetic test, Oncotype DX from Genomic Health, is now offered at Dr. Samadi's Prostate Cancer Center in New York City.
Scientists are reporting a test which can predict which patients are most at risk from aggressive prostate cancer, and whether they suffer an increased chance of treatment failure.
A multicenter team of researchers report that a commercial test designed to rule out the presence of genetic biomarkers of prostate cancer may be accurate enough to exclude the need for repeat prostate biopsies in many — if not most — men.